Amgen buys Micromet for anti-leukemia drug

January 26, 2012

Biotech giant Amgen said Thursday it was buying the German-American cancer research firm Micromet, giving it access to Micromet's promising leukemia therapy.

Amgen said it would pay $1.16 billion for Micromet, founded by a team of to tap the potential of T-cell therapies to fight cancer.

The company, based in Rockville, Maryland, has developed blinatumomab, a T-cell based treatment for and possibly non-Hodgkin's lymphoma that is still undergoing testing.

"Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercializing therapeutics to treat patients with grievous illness," Amgen chief executive Kevin Sharer said in a statement.

The deal is worth $11 a share to Micromet shareholders. The Nasdaq-listed company's price jumped 31.9 percent to $10.92 after the announcement.

California-based Amgen's share price fell 1.4 percent to $68.25.

Explore further: Patient privacy focus of Amgen suit

Related Stories

Patient privacy focus of Amgen suit

January 9, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

Anemia drugs under scrutiny

March 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

FDA may limit anemia drug use for kidney disease

October 14, 2010

(AP) -- The Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.